NCT00386139View on ClinicalTrials.gov

A Safety and Efficacy Trial of the Combination of Aliskiren / Hydrochlorothiazide (HCTZ)(300/12.5 mg and 300/25 mg) Compared to Aliskiren 300 mg in Hypertensive Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

881

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

July 31, 2007

Study Completion Date

July 31, 2007

Conditions
Hypertension
Interventions
DRUG

Aliskiren/HCTZ

Trial Locations (2)

07936

Novartis Pharmaceuticals, East Hanover

Unknown

Investigative Centers

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY

NCT00386139 - A Safety and Efficacy Trial of the Combination of Aliskiren / Hydrochlorothiazide (HCTZ)(300/12.5 mg and 300/25 mg) Compared to Aliskiren 300 mg in Hypertensive Patients | Biotech Hunter | Biotech Hunter